Product Description
Mechanisms of Action: MAP2K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: EMD Serono
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Colorectal Cancer|Melanoma|Ovarian Cancer|Adenocarcinoma|Pancreatic Cancer|Non-Small-Cell Lung Cancer|Acute Myeloid Leukemia|Triple Negative Breast Cancer|Skin Cancer|Brain Cancer
Phase 1: Melanoma|Breast Cancer|Colorectal Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Hepatocellular Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2021-00219 | P2 |
Completed |
Triple Negative Breast Cancer|Brain Cancer|Melanoma|Skin Cancer|Adenocarcinoma|Non-Small-Cell Lung Cancer |
2023-12-08 |
|
| 2013-000902-40 | P2 |
Completed |
Ovarian Cancer |
2017-12-08 |
|
| Phase II trial of pimasertib vs. dacarbazine in N-Ras mutated cutaneous melanoma | P2 |
Completed |
Melanoma |
2016-02-20 |
|
| TCD13388 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2016-02-01 |